Aquestive Therapeutics Inc. (AQST) Added to NASDAQ Biotechnology Index

Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients’ unmet needs and solve therapeutic problems, today announced that NASDAQ has added the company to the NASDAQ Biotechnology Index® (Nasdaq: NBI) effective December 20, 2021.

The NASDAQ Biotechnology Index is designed to track the performance of a set of biotechnology and pharmaceutical companies listed on The Nasdaq Stock Market® (Nasdaq®). Companies in the NBI must meet eligibility requirements, including minimum market capitalization and average daily trading volume, among other criteria. The Index is evaluated annually and serves as the basis for the iShares NASDAQ Biotechnology Index Fund (Nasdaq: IBB). Because of this designation, shares of Aquestive Therapeutics will be included in the portfolios of NBI index funds. The Company expects this to increase institutional ownership in the Company’s shares, both through index fund purchases and potentially by fund managers selecting portfolio stocks.

“We are very proud to represent the pharmaceutical sector as part of the Nasdaq Biotechnology Index. We believe our approach, best-in-class technologies and proven capabilities for drug development are an attractive offering for investors,” commented Keith Kendall, Chief Executive Officer of Aquestive.

You May Also Be Interested In

• Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models
• General Mills, ADM, and Walmart target 40,000 wheat acres
• House of Doge names six-member board after Nasdaq debut